ReviewIranian journal of basic medical sciences2015
Adiponectin: an adipokine with protective features against metabolic syndrome.
Review in Iranian journal of basic medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 115 citations in OpenAlex.
- Enhanced mitigation of diabetic myocardial injury in rats via modulating the adiponectin/IRS-1/PI3K/p-AKT/FOXO-1 signaling by combining methotrexate and insulin.Molecular biology reports · 2026Article
- Hidradenitis suppurativa: epidemiology, diagnosis, molecular pathogenesis and therapy.Molecular biomedicine · 2026Review
- Circulating Adiponectin and Omentin Across Cardiometabolic Phenotypes: Links to Atherogenic Indices in Prediabetes and New-Onset Type 2 Diabetes.International journal of molecular sciences · 2026Article
- Longevity, Centenarians, and Lifestyle: Any ''Tips'' to Live Longer?Current nutrition reports · 2026Review
- Epicardial Adipocytes in Cardiac Pathology and Healing.Cardiovascular drugs and therapy · 2025Review
- Adipokines in preeclampsia: disrupted signaling pathways and novel therapeutic strategies.European journal of medical research · 2025Review
- The Role of Adiponectin andGenes · 2025Review
- Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming.Biomolecules · 2025Review
- Two Sides of Triglycerides in Atherogenesis: An Essential Contributor.Clinical Medicine Insights. Cardiology · 2025Review
- Adiponectin deficiency is a critical factor contributing to cognitive dysfunction in obese mice after sevoflurane exposure.Molecular medicine (Cambridge, Mass.) · 2024Article
- Review
- New advances of adiponectin in regulating obesity and related metabolic syndromes.Journal of pharmaceutical analysis · 2024Review
- Inflammation and Fatty Infiltration Correlates with Rotator Cuff Muscle Atrophy in Hypercholesterolemic Yucatan Microswine.Journal of orthopaedics and sports medicine · 2024Article
- Childhood Obesity: Insight into Kidney Involvement.International journal of molecular sciences · 2023Review
- Association of physical activity with increased PI3K and Akt mRNA levels in adipose tissues of obese and non-obese adults.Scientific reports · 2023Article
- Mechanisms of Oxidative Stress in Metabolic Syndrome.International journal of molecular sciences · 2023Review
- Novel targets for potential therapeutic use in Diabetes mellitus.Diabetology & metabolic syndrome · 2023Review
- Exposure to Heavy Metals and Serum Adiponectin Levels among Workers: A 2-Year Follow-Up Study.Metabolites · 2023Article
- Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial.Frontiers in pharmacology · 2023Article
- The Variants inJournal of multidisciplinary healthcare · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) as a collection of obesity-associated disorders is associated with inflammation, oxidative stress, pro-thrombotic state, elevated risk of developing cardiovascular disease and type 2 diabetes. Adiponectin is one of the most abundant peptide hormones derived from adipose tissue. This protein plays a major role in glucose and lipid metabolism and prevents development of vascular changes. Anti-oxidative and anti-inflammatory effects are the other features of adiponectin. Hypoadiponectinemia is associated with hypertension and pro-thrombotic state. In this review, we discuss the crucial role of adiponectin in prevention of metabolic syndrome considering its effects on the components of this syndrome. Pharmacological interventions and lifestyle modification may increase plasma adiponectin level or tissue sensitivity which seems to be a promising target for prevention and therapeutic approaches of MetS and related diseases.
Indexed as
Identifiers
26124928PMC4475650W2101732322What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.